Thousands of Israeli patients finally get access to critical migraine drug after nearly a year shortage

Israeli health funds have received a British alternative to the medication Slow Darelin 80mg, ending a prolonged shortage that left thousands of patients without access to a critical treatment. The drug shortage, which lasted nearly a year, was previously exposed by local media, sparking concern among patients relying on the medication for managing their conditions. Health officials have now secured an alternative supply to address the supply crisis.

Slow Darelin is prescribed for a range of conditions including migraines, hypertension and tremors. The medication has been essential for many Israeli patients managing chronic conditions, and its absence created significant disruption to treatment plans across the country’s healthcare system.

Patients currently receiving the British alternative are advised to verify its availability through their health fund and have been cautioned against changing their treatment regimen without consulting their doctor. Medical professionals have emphasised that any adjustments to medication should only be made under proper medical supervision to ensure patient safety and maintain therapeutic effectiveness.

While the arrival of the alternative supply represents relief for patients who have endured months without their prescribed medication, questions remain about how such extended shortages can occur within Israel’s healthcare system and what measures will be implemented to prevent similar situations in the future.

Source: Maariv — Original article in Hebrew.